Haemonetics Corp HAE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
-
Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System
-
Haemonetics 1st Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website
-
Sotera Health Appoints Christopher Simon to the Board of Directors
-
Haemonetics Announces CE Mark Certification for the SavvyWire® Pre-Shaped Pressure Guidewire
-
Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2025 Results: August 8, 2024
Trading Information
- Previous Close Price
- $79.80
- Day Range
- $79.24–80.66
- 52-Week Range
- $70.74–97.97
- Bid/Ask
- $72.00 / $84.23
- Market Cap
- $4.11 Bil
- Volume/Avg
- 583,493 / 589,191
Key Statistics
- Price/Earnings (Normalized)
- 20.20
- Price/Sales
- 3.08
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Stock Style Box
- Small Core
- Total Number of Employees
- 3,657
- Website
- https://www.haemonetics.com
Competitors
Valuation
|
Metric
|
HAE
|
MDT
|
|---|---|---|
Price/Earnings (Normalized) | 20.20 | 17.05 |
Price/Book Value | 4.51 | 2.39 |
Price/Sales | 3.08 | 3.62 |
Price/Cash Flow | 17.05 | 15.81 |
Price/Earnings
HAE
MDT
Financial Strength
|
Metric
|
HAE
|
MDT
|
|---|---|---|
Quick Ratio | 2.10 | 1.35 |
Current Ratio | 3.76 | 2.13 |
Interest Coverage | 37.82 | 7.66 |
Quick Ratio
HAE
MDT
Profitability
|
Metric
|
HAE
|
MDT
|
|---|---|---|
Return on Assets (Normalized) | 9.27% | 7.66% |
Return on Equity (Normalized) | 22.15% | 13.69% |
Return on Invested Capital (Normalized) | 11.42% | 9.84% |
Return on Assets
HAE
MDT
Medical Instruments & Supplies Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Intuitive Surgical Inc
ISRG
| Pgbdshtwbj | Skjfc | $170.3 Bil | |||
| Becton Dickinson & Co
BDX
| Qhcjhnry | Ykmfbn | $69.8 Bil | |||
| Alcon Inc
ALC
| Vssjgdmm | Tnwns | $49.3 Bil | |||
| ResMed Inc
RMD
| Qzssdkzgrq | Zvqfq | $35.1 Bil | |||
| Coloplast AS ADR
CLPBY
| Xsvzdvxglr | Gsk | $29.7 Bil | |||
| West Pharmaceutical Services Inc
WST
| Ndpskllsg | Yjqw | $22.6 Bil | |||
| The Cooper Companies Inc
COO
| Sjjxrmkpf | Dmhglb | $21.9 Bil | |||
| Baxter International Inc
BAX
| Nxsmhtndg | Qtrnxzy | $19.9 Bil | |||
| Align Technology Inc
ALGN
| Nfwktghmq | Xbyzzm | $19.0 Bil | |||
| Hologic Inc
HOLX
| Bbsbhbfd | Qlggln | $18.8 Bil |
United States